Multiple Myeloma Clinical Trial

The PRONTO Study, a Global Phase 2b Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis

Summary

This is a global, multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who had a hematologic response to previous treatment for their amyloidosis (e.g., chemotherapy, autologous stem cell transplant [ASCT]) and have persistent cardiac dysfunction.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥18 years
Confirmed diagnosis of systemic AL amyloidosis
≥1 prior systemic plasma cell dyscrasia therapy with at least a partial hematologic response
Cardiac involvement
NT-proBNP ≥650

Exclusion Criteria:

Non-AL amyloidosis
Meets the International Myeloma Working Group (IMWG) definition of Multiple Myeloma
NT-proBNP >5000
Received Plasma cell directed chemotherapy within 6 months
Received autologous stem cell transplant (ASCT) within 12 months

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

129

Study ID:

NCT02632786

Recruitment Status:

Completed

Sponsor:

Prothena Biosciences Ltd.

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 36 Locations for this study

See Locations Near You

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 2

Estimated Enrollment:

129

Study ID:

NCT02632786

Recruitment Status:

Completed

Sponsor:


Prothena Biosciences Ltd.

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider